“HRT” covers several meaningfully different therapies. The right form for you depends on your symptoms, your medical history, and whether you still have a uterus.

Transdermal estradiol (patch, gel, spray)

Generally the first-line form for most women who are starting systemic HRT. The key reason: transdermal delivery bypasses first-pass liver metabolism, which eliminates the small increase in venous thromboembolism (VTE, “blood clot”) risk that has been associated with oral estrogen. For women with any clot risk factors — family history, migraine with aura, higher BMI — this distinction matters.

Practical differences among transdermal forms:

  • Patch: changed once or twice a week; steady delivery; convenient but some users react to the adhesive
  • Gel: applied daily to arm or thigh; flexible dose adjustment; can transfer via skin contact so care needed around others
  • Spray: once-daily; fast-drying; similar caveats to gel

Oral estrogen

Still used, still effective, and sometimes preferred by patients who find patches inconvenient or reactive. The clot-risk consideration is the main reason it’s typically second-line in 2026 guidance rather than first-line.

Micronized progesterone (oral)

If you have a uterus, unopposed estrogen isn’t an option — you need progesterone to protect the endometrial lining. Micronized progesterone, usually dosed at 100mg at night, is the most common choice in current practice. It’s bioidentical, FDA-approved, and many women report it also helps sleep as a secondary benefit.

Synthetic progestins (medroxyprogesterone, norethindrone) are still prescribed but less commonly in contemporary menopause practice.

Vaginal estrogen (cream, ring, tablet)

A separate category worth understanding. Vaginal estrogen treats the genitourinary syndrome of menopause (GSM) — dryness, painful sex, urinary frequency, recurrent UTIs — with minimal systemic absorption. That minimal absorption is important: vaginal estrogen is often usable even for women for whom systemic HRT isn’t appropriate, including some cancer survivors under specialist care.

💡 Systemic and vaginal aren't mutually exclusive

Many women on systemic HRT still benefit from adding low-dose vaginal estrogen if genitourinary symptoms are the dominant issue. They work on different things.

Testosterone

Off-label in the United States for the treatment of low libido in menopause, though routinely used in the UK and Australia. Evidence supports benefit for libido specifically. Not first-line, and dosing matters — supra-physiologic levels cause side effects.

DHEA

Available as vaginal DHEA (prasterone/Intrarosa) for genitourinary symptoms. Oral DHEA is widely sold as a supplement with inconsistent quality control; clinical use of oral DHEA for menopause remains limited.

Combined products

Some prescribing is simplified by combination patches or oral products delivering estrogen plus progestin together. Convenient, and appropriate for many women. Slightly less flexibility if you need to adjust one component independently of the other.

How a good clinician picks for you

The decision tree goes roughly: start with transdermal estradiol for most women; add micronized progesterone if you have a uterus; consider adding vaginal estrogen if genitourinary symptoms persist; consider testosterone if libido is the priority and everything else is addressed.

The wrong answer is “this is the one I always prescribe.” The right clinician will choose the form that matches your risk profile and symptom pattern.